Mohsen Arani, MD
Hematology & Oncology · The Woodlands, TXNPI 1821097072
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 18.4%. Reporting peaked in 2024 at $30,226 and has fallen 67.5% since, to $9,838 in 2025. Among hematology & oncology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,202 payments — averaging $59.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Onmark, Inc.$24K
- Gilead$8K
- Dova Pharmaceuticals$7K
- Coherus Oncology, Inc.$7K
- Johnson & Johnson$6K
- Janssen Scientific Affairs, LLC$5K
- plus $70K from 54 others
Across 5 payments — averaging $3148.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$16K
What the payments were for
- Consulting fees$66,96351%
- Speaking & faculty fees$6,2005%
- Travel & lodging$8,2236%
- Food & beverage$48,43737%
- Education$1,3741%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DOPTELET$6,881
- IMBRUVICA$6,371
- Udenyca$6,319
- Trodelvy$5,770
- FOUNDATIONACT$4,498
- FOUNDATIONFOCUS$4,498
- FOUNDATIONONE CDX$4,498
- FOUNDATIONONE HEME$4,498
- FOUNDATIONONE$4,498
- VYXEOS$3,856
- DARZALEX$2,472
- SARCLISA$2,442
- Rituxan$1,934
- GAZYVA$1,934
- POLIVY$1,934
- ADCETRIS$1,619
- CALQUENCE$1,618
- Yescarta$1,580
- Monoferric$1,500
- COSELA$1,500
How this compares
$131,197 in reported general payments places this provider in the 90th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 51 | $947,607 |
| ErleadaApalutamide | 53 | $788,992 |
| Lenalidomide | 37 | $553,198 |
| CalquenceAcalabrutinib Maleate | 33 | $478,257 |
| JakafiRuxolitinib Phosphate | 25 | $423,660 |
| AlecensaAlectinib Hcl | 18 | $335,366 |
| CabometyxCabozantinib S-Malate | 11 | $315,405 |
| XtandiEnzalutamide | 22 | $295,152 |
| OjjaaraMomelotinib Dihydrochloride | 11 | $291,441 |
| JaypircaPirtobrutinib | 11 | $249,827 |
| VerzenioAbemaciclib | 15 | $216,537 |
| PromactaEltrombopag Olamine | 12 | $155,271 |
| XareltoRivaroxaban | 137 | $130,684 |
| EliquisApixaban | 156 | $130,499 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 14 | $95,466 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $1,430 | $947,60751 claims |
| Johnson & JohnsonErleada, Xarelto | $6,203 | $919,675190 claims |
| AstraZenecaCalquence | $4,609 | $478,25733 claims |
| Lilly USA, LLCJaypirca, Verzenio | $700 | $466,36326 claims |
| Incyte CorporationJakafi | $596 | $423,66025 claims |
| Genentech USA, Inc.Alecensa | $2,625 | $335,36618 claims |
| Astellas Pharma US IncXtandi | $933 | $295,15222 claims |
| GSKOjjaara | $3,411 | $291,44111 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid, Entyvio | $755 | $187,91125 claims |
| NovartisPromacta | $2,498 | $155,27112 claims |
| PfizerEliquis | $1,845 | $130,499156 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 838 hematology & oncology providers in Texas.
Other hematology & oncology in The Woodlands
- Devesh PandyaHouston$1.8M
- Elias JabbourHouston$1.3M
- Asad DeanFort Worth$1.1M
- Habte YimerTyler$934K
- Edward PearsonDallas$900K
- Naval DaverHouston$853K
- Christopher MaiselDallas$713K
- Clifton LaymanEl Paso$645K
- Jorge Cortes-FrancoHouston$627K
- Timothy FenskeSan Antonio$626K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.